Menu Search
Equities

Otsuka Holdings Co Ltd

4578:TYO

Otsuka Holdings Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)8,991.00
  • Today's Change39.00 / 0.44%
  • Shares traded480.80k
  • 1 Year change+61.16%
  • Beta0.9930
Data delayed at least 20 minutes, as of Nov 22 2024 04:33 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy3
Outperform4
Hold4
Sell0
Strong Sell0

Share price forecast in JPY

The 11 analysts offering 12 month price targets for Otsuka Holdings Co Ltd have a median target of 9,300.00, with a high estimate of 10,800.00 and a low estimate of 6,100.00. The median estimate represents a 3.89% increase from the last price of 8,952.00.
High20.6%10,800.00
Med3.9%9,300.00
Low-31.9%6,100.00

Dividends in JPY

In 2023, Otsuka Holdings Co Ltd reported a dividend of 110.00 JPY, which represents a 10.00% increase over last year. The 9 analysts covering the company expect dividends of 121.78 JPY for the upcoming fiscal year, an increase of 10.71%.
Div growth (TTM)10.00%
More ▼

Earnings history & estimates in JPY

On Oct 31, 2024, Otsuka Holdings Co Ltd reported 3rd quarter 2024 earnings of 154.72 per share.
The next earnings announcement is expected on Feb 11, 2025.
Average growth rate+57.74%
Otsuka Holdings Co Ltd reported annual 2023 earnings of 224.10 per share on Feb 13, 2024.
Average growth rate-0.34%
More ▼

Revenue history & estimates in JPY

Otsuka Holdings Co., Ltd. had 3rd quarter 2024 revenues of 621.15m. This bettered the 601.73m consensus of the 5 analysts covering the company. This was 38.54% above the prior year's 3rd quarter results.
Average growth rate+4.16%
Otsuka Holdings Co., Ltd. had revenues for the full year 2023 of 2.02bn. This was 16.14% above the prior year's results.
Average growth rate+9.84%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.